| Original language | English |
|---|---|
| Pages (from-to) | 740 |
| Number of pages | 1 |
| Journal | Leukemia |
| Volume | 29 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 9 2015 |
ASJC Scopus subject areas
- Hematology
- Cancer Research
- Anesthesiology and Pain Medicine
- Medicine(all)
Cite this
Barosi, G., & Gale, R. P. (2015). Reply to Passamonti et al: Ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia, 29(3), 740. https://doi.org/10.1038/leu.2014.312
Reply to Passamonti et al : Ruxolitinib and survival improvement in patients with myelofibrosis. / Barosi, G.; Gale, R. P.
In: Leukemia, Vol. 29, No. 3, 09.03.2015, p. 740.Research output: Contribution to journal › Article
Barosi, G & Gale, RP 2015, 'Reply to Passamonti et al: Ruxolitinib and survival improvement in patients with myelofibrosis', Leukemia, vol. 29, no. 3, pp. 740. https://doi.org/10.1038/leu.2014.312
Barosi G, Gale RP. Reply to Passamonti et al: Ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia. 2015 Mar 9;29(3):740. https://doi.org/10.1038/leu.2014.312
@article{061320bbe8af4e0cbd0659aea1c20980,
title = "Reply to Passamonti et al: Ruxolitinib and survival improvement in patients with myelofibrosis",
author = "G. Barosi and Gale, {R. P.}",
year = "2015",
month = "3",
day = "9",
doi = "10.1038/leu.2014.312",
language = "English",
volume = "29",
pages = "740",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",
}
TY - JOUR
T1 - Reply to Passamonti et al
T2 - Ruxolitinib and survival improvement in patients with myelofibrosis
AU - Barosi, G.
AU - Gale, R. P.
PY - 2015/3/9
Y1 - 2015/3/9
UR - http://www.scopus.com/inward/record.url?scp=84924598223&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924598223&partnerID=8YFLogxK
U2 - 10.1038/leu.2014.312
DO - 10.1038/leu.2014.312
M3 - Article
C2 - 25363668
AN - SCOPUS:84924598223
VL - 29
SP - 740
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 3
ER -